Review



anti pd l1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Proteintech anti pd l1
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Anti Pd L1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 655 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/PD-L1%2FCD274+(C-terminal)+Antibody/pmc13620340-49-40-42
    Average 96 stars, based on 655 article reviews
    anti pd l1 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "SLAMF6 Enhances the Efficacy of Anti‐ PD ‐ L1 Immunotherapy in CRC Through the STAT1 / CXCL10 Signaling Axis"

    Article Title: SLAMF6 Enhances the Efficacy of Anti‐ PD ‐ L1 Immunotherapy in CRC Through the STAT1 / CXCL10 Signaling Axis

    Journal: Cancer Science

    doi: 10.1111/cas.70530

    SLAMF6 enhances anti‐PD‐L1 immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Figure Legend Snippet: SLAMF6 enhances anti‐PD‐L1 immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.

    Techniques Used:

    Related Articles

    Incubation:

    Article Title: Exogenous PD-L1 binds to PD-1 to alleviate and prevent autism-like behaviors in maternal immune activation-induced male offspring mice.
    Article Snippet: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder caused by the interaction of multiple pathogenic factors.. Epidemiological studies and animal experiments indicate that maternal immune activation (MIA) is closely related to the development of ASD in offspring.. A large number of pro-inflammatory cytokines are transferred from the placenta to the fetal brain during MIA, which impedes fetal neurodevelopment and is accompanied by activation of immune cells and microglia.

    other:

    Article Title: A novel identified epithelial ligand-receptor-associated gene signature highlights POPDC3 as a potential therapy target for non-small cell lung cancer
    Article Snippet: The primary antibodies used were the following: anti-POPDC3 (1:2000; 11800-1-AP; ProteinTech), anti-anillin (ANLN, 1:2000; A03997-1; BOSTER), anti-Desmoglein 2 (DSG2, 1:2000; BA3606; BOSTER), anti-CUB domain containing protein 1 (CDCP1, 1:2000; PB0978; BOSTER), anti-stanniocalcin 2 (STC2, 1:2000; 60063-1-lg; proteintech), anti-RHOV (1:500; sc-515072; Santa Cruz Biotechnology), anti-E-cadherin (1:2000; BM4166; BOSTER), anti-N-cadherin (1:2000; BA0673; BOSTER), anti-Vimentin (1:2000; BM4029; BOSTER), anti-SNAI1 (1:2000; A00716-2; BOSTER), anti-Slug (1:2000; PB9439; BOSTER), anti-Bcl2 (1:2000; A00040-1; BOSTER), anti-Bax (1:2000; A00183; BOSTER), anti-Ki67 (1:4000; ab16667; Abcam), anti-GAPDH (1:4000; ab8245; Abcam), anti-CD4 (1:1600; ab237722; Abcam), anti-PD-1 (1:1000; 18106-1-AP; ProteinTech).

    Article Title: SARS-CoV-2 infection in brain tumors and the association with alterations in the tumor immune microenvironment.
    Article Snippet: The following antibodies were used in the current study: anti-SARS-CoV-2-NP (40143-MM05, 1:100; Sino Biological, Beijing, china); anti-NRP1 (60067-1-Ig, 1:200; Proteintech, Rsemont, IL, USA); rabbit anti-CD31 (77699S, 1:500; Cell Signaling Technology, Danvers, MA, USA); rabbit anti-ACE2 (10108-T24, 1:200; Sino Biological); rabbit anti-TMPRSS2 (14437-1-AP, 1:200; Proteintech); mouse anti-CD147/BSG (66443-1-Ig, 1:200; Proteintech); anti-CD3 (85061s, 1:300; CST, Danvers, MA, USA); anti-CD4 (ab133616, 1:1000; Abcam, Cambridge, United Kingdom); anti-CD8 (ab93278, 1:200; Abcam); anti-CD8 (66868-1-Ig, 1:200; Proteintech); anti-CD20 (ab9475, 1:1000; Abcam); anti-CD68 (76437s, 1:500; CST); anti-C3 (ET7106-75, 1:100; Huabio, Fort Worth, TX, USA); anti-C1q (HA721439, 1:100; Huabio); anti-IgG (ZA-0448; ZSGB-BIO, Beijing, China); anti-IgM (ZA-0450; ZSGB-BIO); anti-TTF1 (66034-1-Ig, 1:200; Proteintech); rabbit anti-GFAP (16825-1-AP, 1:200; Proteintech); anti-MUC1 (HA601142, 1:200; Huabio); anti-panCK (HA601138, 1:200; Huabio); anti-PD-1 (18106-1-AP, 1:200; Proteintech); antiIFN-γ (AB231036, 1:200; Abcam); and anti-FOXP3 (22228-1- AP, 1:200; Proteintech).

    Article Title: A novel identified epithelial ligand-receptor-associated gene signature highlights POPDC3 as a potential therapy target for non-small cell lung cancer.
    Article Snippet: The primary antibodies used were the following: anti-POPDC3 (1:2000; 11800-1-AP; ProteinTech), anti-anillin (ANLN, 1:2000; A03997-1; BOSTER), anti-Desmoglein 2 (DSG2, 1:2000; BA3606; BOSTER), anti-CUB domain containing protein 1 (CDCP1, 1:2000; PB0978; BOSTER), anti-stanniocalcin 2 (STC2, 1:2000; 60063-1- lg; proteintech), anti-RHOV (1:500; sc-515072; Santa Cruz Biotechnology), anti-Ecadherin (1:2000; BM4166; BOSTER), anti-N-cadherin (1:2000; BA0673; BOSTER), anti-Vimentin (1:2000; BM4029; BOSTER), anti-SNAI1 (1:2000; A00716-2; BOSTER), anti-Slug (1:2000; PB9439; BOSTER), anti-Bcl2 (1:2000; A00040-1; BOSTER), anti-Bax (1:2000; A00183; BOSTER), anti-Ki67 (1:4000; ab16667; Abcam), anti-GAPDH (1:4000; ab8245; Abcam), anti-CD4 (1:1600; ab237722; Abcam), anti-PD-1 (1:1000; 18106-1-AP; ProteinTech).

    Article Title: Zuojin capsule improves T cell exhaustion and tumor immune microenvironment of hepatocellular carcinoma through the mTOR-eIF4E/p70S6K-CDK1 pathway
    Article Snippet: Anti-PD-1 (BE0146) and anti-PD-1 (66220-1-Ig) were purchased from Bioxcell and Proteintech Group, Inc, respectively.

    Membrane:

    Article Title: Exogenous PD-L1 binds to PD-1 to alleviate and prevent autism-like behaviors in maternal immune activation-induced male offspring mice.
    Article Snippet: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder caused by the interaction of multiple pathogenic factors.. Epidemiological studies and animal experiments indicate that maternal immune activation (MIA) is closely related to the development of ASD in offspring.. A large number of pro-inflammatory cytokines are transferred from the placenta to the fetal brain during MIA, which impedes fetal neurodevelopment and is accompanied by activation of immune cells and microglia.

    Saline:

    Article Title: Exogenous PD-L1 binds to PD-1 to alleviate and prevent autism-like behaviors in maternal immune activation-induced male offspring mice.
    Article Snippet: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder caused by the interaction of multiple pathogenic factors.. Epidemiological studies and animal experiments indicate that maternal immune activation (MIA) is closely related to the development of ASD in offspring.. A large number of pro-inflammatory cytokines are transferred from the placenta to the fetal brain during MIA, which impedes fetal neurodevelopment and is accompanied by activation of immune cells and microglia.

    Western Blot:

    Article Title: BMP9 Potentiates Immunotherapy in Triple-Negative Breast Cancer by Suppressing Tregs Infiltration via the PRKDC-CCL2 Axis.
    Article Snippet: Immunotherapy represents a pivotal strategy for triple-negative breast cancer (TNBC), yet its efficacy is constrained by the immunosuppressive tumor microenvironment (TME).. In this study, we demonstrate that bone morphogenetic protein-9 (BMP9) inhibits tumor growth and reprograms the immune TME in orthotopic TNBC models, primarily by attenuating regulatory T cells (Tregs) infiltration.. Tregs depletion abrogates si-BMP9mediated tumor promotion.

    Immunohistochemistry:

    Article Title: BMP9 Potentiates Immunotherapy in Triple-Negative Breast Cancer by Suppressing Tregs Infiltration via the PRKDC-CCL2 Axis.
    Article Snippet: Immunotherapy represents a pivotal strategy for triple-negative breast cancer (TNBC), yet its efficacy is constrained by the immunosuppressive tumor microenvironment (TME).. In this study, we demonstrate that bone morphogenetic protein-9 (BMP9) inhibits tumor growth and reprograms the immune TME in orthotopic TNBC models, primarily by attenuating regulatory T cells (Tregs) infiltration.. Tregs depletion abrogates si-BMP9mediated tumor promotion.



    Similar Products

    95
    MedChemExpress nti pd 1 antibody
    Nti Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/Anti-Mouse+PD-1+Antibody/10__1016_slash_j__jncc__2026__08__004-79-8-20
    Average 95 stars, based on 1 article reviews
    nti pd 1 antibody - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    96
    Proteintech anti pd l1
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Anti Pd L1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/PD-L1%2FCD274+(C-terminal)+Antibody/pmc13620340-49-40-42
    Average 96 stars, based on 1 article reviews
    anti pd l1 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    99
    Bio X Cell be0146 critical
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Be0146 Critical, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/InVivoMAb+anti-mouse+PD-1/pm42789388-293-49-47
    Average 99 stars, based on 1 article reviews
    be0146 critical - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Bio X Cell αpd 1
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    αpd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/InVivoMAb+anti-mouse+PD-1/pm42786271-151-0-2
    Average 99 stars, based on 1 article reviews
    αpd 1 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    98
    Bio X Cell anti pd 1 monoclonal antibody
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Anti Pd 1 Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/pm42785687-51-0-8
    Average 98 stars, based on 1 article reviews
    anti pd 1 monoclonal antibody - by Bioz Stars, 2026-10
    98/100 stars
      Buy from Supplier

    99
    Bio X Cell anti pd 1
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Anti Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/InVivoMAb+anti-mouse+PD-1/10__1186_slash_s13046___026___03837___w-107-28-29
    Average 99 stars, based on 1 article reviews
    anti pd 1 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Bio X Cell anti pd 1 antibody
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Anti Pd 1 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/InVivoMAb+anti-mouse+PD-1/pm42771712-483-5-8
    Average 99 stars, based on 1 article reviews
    anti pd 1 antibody - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Bio X Cell anti pd1 cd279
    <t>SLAMF6</t> <t>enhances</t> <t>anti‐PD‐L1</t> immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.
    Anti Pd1 Cd279, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/InVivoMAb+anti-mouse+PD-1/10__1158_slash_0008___5472__can___26___0770-61-10-14
    Average 99 stars, based on 1 article reviews
    anti pd1 cd279 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Bio X Cell invivoplus anti mouse pd 1 cd279
    ( A ) Schematic of the <t>anti-PD-1</t> treatment experiments. ( B-C ) Primary growth of Py8119 tumors ( B ) and tumor-free survival from two independent experiments ( C ). n=6,5,5 and 6 mice in ( B ); n=12,12,10, and 12 mice in ( C ). ( D ) Survival in the Py8119 lung metastasis model. n=10. ( E-F ) Progression-free survival of MC38 tumors ( E ) and pie charts showing treatment responses in each group ( F ). n=10. ( G ) Schematic of ASO and T cell transfer treatment in the MC38-Ova model. ( H-J ) Individual tumor growth curves ( H ), final tumor volumes ( I ), and maximal tumor reduction ratio ( J ) after combined treatment. Numbers in ( H ) indicate the fraction of large and small tumors based on the cutoff line. In ( J ), the maximal tumor reduction ratio was calculated as the minimum tumor volume after combined treatment divided by the pretreatment tumor volume and is shown for individual tumors (left) and by group (right). Control mice received PBS. n=10, 22, and 22 tumors. Data are shown as mean ± SEM. Two-way ANOVA ( B ), log-rank (Mantel-Cox) test ( C, D, E ), and two-tailed unpaired Student’s t test ( I, J ).
    Invivoplus Anti Mouse Pd 1 Cd279, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+pd+1/InVivoMAb+anti-mouse+PD-1/pmc13623212-1238-0-7
    Average 99 stars, based on 1 article reviews
    invivoplus anti mouse pd 1 cd279 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    Image Search Results


    SLAMF6 enhances anti‐PD‐L1 immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.

    Journal: Cancer Science

    Article Title: SLAMF6 Enhances the Efficacy of Anti‐ PD ‐ L1 Immunotherapy in CRC Through the STAT1 / CXCL10 Signaling Axis

    doi: 10.1111/cas.70530

    Figure Lengend Snippet: SLAMF6 enhances anti‐PD‐L1 immunotherapy in CRC via the STAT1/CXCL10 axis. SLAMF6 activates STAT1 to upregulate CXCL10, promoting CD8 + T‐cell recruitment into CRC tumor microenvironment. Together with anti‐PD‐L1, this enhances ICI efficacy.

    Article Snippet: The primary antibodies used in this study were as follows: anti‐SLAMF6 (1:100, Abcam, ab213690), anti‐CD3 (1:100, Abcam, ab16669), anti‐CD8 (1:500, Cell Signaling Technology, #98941, Danvers, MA, USA), anti‐Ki67 (1:200, Proteintech, 27309‐1‐AP), anti‐CXCL10 (1:100, absin, abs135937), anti‐IFN‐γ (1:300, Proteintech, 15365‐1‐AP), and anti‐PD‐L1 (1:1000, Proteintech, 28076‐1‐AP).

    Techniques:

    ( A ) Schematic of the anti-PD-1 treatment experiments. ( B-C ) Primary growth of Py8119 tumors ( B ) and tumor-free survival from two independent experiments ( C ). n=6,5,5 and 6 mice in ( B ); n=12,12,10, and 12 mice in ( C ). ( D ) Survival in the Py8119 lung metastasis model. n=10. ( E-F ) Progression-free survival of MC38 tumors ( E ) and pie charts showing treatment responses in each group ( F ). n=10. ( G ) Schematic of ASO and T cell transfer treatment in the MC38-Ova model. ( H-J ) Individual tumor growth curves ( H ), final tumor volumes ( I ), and maximal tumor reduction ratio ( J ) after combined treatment. Numbers in ( H ) indicate the fraction of large and small tumors based on the cutoff line. In ( J ), the maximal tumor reduction ratio was calculated as the minimum tumor volume after combined treatment divided by the pretreatment tumor volume and is shown for individual tumors (left) and by group (right). Control mice received PBS. n=10, 22, and 22 tumors. Data are shown as mean ± SEM. Two-way ANOVA ( B ), log-rank (Mantel-Cox) test ( C, D, E ), and two-tailed unpaired Student’s t test ( I, J ).

    Journal: Cell metabolism

    Article Title: Host Metadherin Coordinates Hepatic Lipid metabolism and CD8 + T-Cell Immunity to Promote Tumor Progression

    doi: 10.1016/j.cmet.2026.08.003

    Figure Lengend Snippet: ( A ) Schematic of the anti-PD-1 treatment experiments. ( B-C ) Primary growth of Py8119 tumors ( B ) and tumor-free survival from two independent experiments ( C ). n=6,5,5 and 6 mice in ( B ); n=12,12,10, and 12 mice in ( C ). ( D ) Survival in the Py8119 lung metastasis model. n=10. ( E-F ) Progression-free survival of MC38 tumors ( E ) and pie charts showing treatment responses in each group ( F ). n=10. ( G ) Schematic of ASO and T cell transfer treatment in the MC38-Ova model. ( H-J ) Individual tumor growth curves ( H ), final tumor volumes ( I ), and maximal tumor reduction ratio ( J ) after combined treatment. Numbers in ( H ) indicate the fraction of large and small tumors based on the cutoff line. In ( J ), the maximal tumor reduction ratio was calculated as the minimum tumor volume after combined treatment divided by the pretreatment tumor volume and is shown for individual tumors (left) and by group (right). Control mice received PBS. n=10, 22, and 22 tumors. Data are shown as mean ± SEM. Two-way ANOVA ( B ), log-rank (Mantel-Cox) test ( C, D, E ), and two-tailed unpaired Student’s t test ( I, J ).

    Article Snippet: InVivoPlus anti-mouse PD-1 (CD279) (clone RMP1-14) , Bio X Cell , Cat#BE0146; RRID: AB_10949053.

    Techniques: Control, Two Tailed Test